Nuclera gains £1.14m funding from Innovate UK
June 7, 2024Research and Development Innovate UK, Nuclera, Pharmacy, grants
Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.
FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia
June 7, 2024Medical Communications FDA, Geron, Haematology, anaemia, mds
Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of …
AbbVie initiates phase 3 multiple myeloma trial
June 6, 2024Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …
Syngene launches new platform for protein production
June 6, 2024Research and Development ExcellGene, Pharmacy, Syngene, platform, protein production
Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology …
Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis
June 5, 2024Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar
Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
June 5, 2024Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …
Quince Therapeutics gains FDA Fast Track Designation for EryDex System
June 4, 2024Medical Communications EryDex, FDA, Quince Therapeutics, Rare Diseases, fast track designation
Quince Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its EryDex …
Oryzon Genomics announces publication of phase 2a ALICE trial results
June 4, 2024Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …
CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment
June 3, 2024Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) alongside pemetrexed and platinum-based chemotherapy, has been recommended for approval in the EU for …
Gilead and Arcus announce results from colorectal cancer treatment trial
June 3, 2024Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer
Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …
AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC
May 31, 2024Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
Merck to acquire EyeBio for an upfront $1.3bn
May 31, 2024Business Services EyeBio, Merck, Opthalmology, acquisition, ophthalmology
Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced that the two companies have …
Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases
May 30, 2024Medical Communications Eli Lilly, Pharmacy, Unicef, investment, noncommunicable diseases
Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand …
Full-Life Technologies’ IND application for prostate cancer cleared by FDA
May 30, 2024Medical Communications Full-Life Technologies, IND, Oncology, prostate cancer
Full-Life Technologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application …
Sanofi’s Sarclisa accepted for FDA priority review
May 29, 2024Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
May 29, 2024Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda
Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
May 28, 2024Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
Eli Lilly increases manufacturing investment to $9bn at new Indiana site
May 28, 2024Manufacturing and Production Diabetes, Eli Lilly, Indiana, investment, manufacturing
Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with …
OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments
May 24, 2024Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases
OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …
Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies
May 24, 2024Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies
Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …
Latest content
FibroFind appoints Lee Borthwick as CEO
